Drugs / Allogeneic Adipose-Derived Mesenchymal Stromal Cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05553132 | Aug 2023 → Dec 2026 expected | cartilage development disorder | Daniel B. F. Saris | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07635875 | Apr 2026 → Apr 2028 expected | reactive cutaneous fibrous lesion | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic adipose-Derived Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07635875 ↗ |
| Known as | AMSCs | “Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier” NCT05553132 ↗ |
| Action | Restore | “MSCs or Mesenchymal Stem Cells are naturally occurring cells that provide growth factors and cell signals that play a role in tissue repair.” NCT05553132 ↗ |
| Modality | Cell therapy | “allogeneic adipose-derived mesenchymal stem cells (AMSCs)” NCT05553132 ↗ |